Crinetics Pharmaceuticals, Inc. (CRNX): Price and Financial Metrics

Crinetics Pharmaceuticals, Inc. (CRNX): $36.85

0.13 (+0.35%)

POWR Rating

Component Grades








CRNX Price/Volume Stats

Current price $36.85 52-week high $40.50
Prev. close $36.72 52-week low $15.23
Day low $36.48 Volume 349,000
Day high $37.60 Avg. volume 638,257
50-day MA $36.50 Dividend yield N/A
200-day MA $26.90 Market Cap 2.46B

CRNX Stock Price Chart Interactive Chart >


  • Value is the dimension where CRNX ranks best; there it ranks ahead of 36.43% of US stocks.
  • CRNX's strongest trending metric is Sentiment; it's been moving down over the last 26 weeks.
  • CRNX ranks lowest in Stability; there it ranks in the 9th percentile.

CRNX Stock Summary

  • CRINETICS PHARMACEUTICALS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 9.41% of US listed stocks.
  • With a price/sales ratio of 494.56, CRINETICS PHARMACEUTICALS INC has a higher such ratio than 99.03% of stocks in our set.
  • With a year-over-year growth in debt of 1,470.47%, CRINETICS PHARMACEUTICALS INC's debt growth rate surpasses 99.3% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to CRINETICS PHARMACEUTICALS INC, a group of peers worth examining would be MIST, OPT, LYRA, ENVX, and INDI.
  • Visit CRNX's SEC page to see the company's official filings. To visit the company's web site, go to

CRNX Valuation Summary

  • In comparison to the median Healthcare stock, CRNX's price/sales ratio is 22777.27% higher, now standing at 503.3.
  • Over the past 66 months, CRNX's price/sales ratio has gone up 265.4.

Below are key valuation metrics over time for CRNX.

Stock Date P/S P/B P/E EV/EBIT
CRNX 2023-12-29 503.3 4.3 -11.9 -11.5
CRNX 2023-12-28 505.7 4.4 -12.0 -11.5
CRNX 2023-12-27 514.7 4.4 -12.2 -11.7
CRNX 2023-12-26 510.8 4.4 -12.1 -11.6
CRNX 2023-12-22 508.0 4.4 -12.0 -11.6
CRNX 2023-12-21 491.6 4.2 -11.6 -11.2

CRNX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CRNX has a Quality Grade of C, ranking ahead of 31.2% of graded US stocks.
  • CRNX's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows CRNX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.000 NA -1.476
2021-03-31 0.000 NA -1.211
2020-12-31 0.000 1 -1.064
2020-09-30 0.002 1 -0.952
2020-06-30 0.006 1 -0.913
2020-03-31 0.007 1 -0.741

CRNX Price Target

For more insight on analysts targets of CRNX, see our CRNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $37.40 Average Broker Recommendation 1.4 (Strong Buy)

Crinetics Pharmaceuticals, Inc. (CRNX) Company Bio

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is based in San Diego, California.

CRNX Latest News Stream

Event/Time News Detail
Loading, please wait...

CRNX Latest Social Stream

Loading social stream, please wait...

View Full CRNX Social Stream

Latest CRNX News From Around the Web

Below are the latest news stories about CRINETICS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CRNX as an investment opportunity.

Insider Sell: Chief Med and Dev Officer Dana Pizzuti Sells 9,583 Shares of Crinetics ...

On December 21, 2023, Chief Med and Dev Officer Dana Pizzuti sold 9,583 shares of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), as indicated by an SEC Filing.

Yahoo | December 23, 2023

Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome

Significant Reductions in Frequency and Intensity of Both Bowel Movements and Flushing Episodes Were Observed Paltusotine was Well-Tolerated with an Overall Pharmacokinetic Profile that was Consistent with Prior Studies Phase 2 Study Enrollment is Complete (N=36), and Topline Results Expected in 1H 2024 Management to Host a Conference Call Today at 5:00 p.m. Eastern Time SAN DIEGO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive initial f

Yahoo | December 18, 2023

Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that on December 10, 2023, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 94,000 shares of its common stock to six new non-execu

Yahoo | December 11, 2023

12 Stocks Billionaire Steve Cohen Just Bought and Sold

In this article, we’re going to take a look at 12 stocks billionaire Steve Cohen just bought and sold. To jump ahead to see the top picks that made our list, follow this link to read about the 5 Stocks Billionaire Steve Cohen just Bought and Sold. Billionaire Steve Cohen is one of the most […]

Yahoo | December 3, 2023

Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in fireside chats at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida and the Piper Sandler 35th Annual Healthcare Conference in New York City. Details of the fireside chats are as follows: 6th Annual Evercore ISI HealthCONx Conference:Date: Tuesday, November 28, 2023Time: 3:50 p.m. Eastern Time Piper Sandler 35th Annual Healthcar

Yahoo | November 20, 2023

Read More 'CRNX' Stories Here

CRNX Price Returns

1-mo -0.89%
3-mo 15.84%
6-mo 123.06%
1-year 88.20%
3-year 144.85%
5-year 53.35%
YTD 3.57%
2023 94.43%
2022 -35.59%
2021 101.35%
2020 -43.76%
2019 -16.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!